SillaJen, Inc. (215600.KQ)
KRW 2565.0
(0.79%)
KRW 2565.0
(0.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -13.89 Billion KRW | -636.33% |
| 2022 | 2.59 Billion KRW | 108.02% |
| 2021 | -32.29 Billion KRW | -427.28% |
| 2020 | 9.86 Billion KRW | 1160.17% |
| 2019 | -930.75 Million KRW | 95.68% |
| 2018 | -21.52 Billion KRW | 41.23% |
| 2017 | -36.62 Billion KRW | -574.96% |
| 2016 | 7.71 Billion KRW | 116.98% |
| 2015 | -45.42 Billion KRW | -532.56% |
| 2014 | 10.5 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -98.48 Billion KRW | -1070.56% |
| 2024 Q1 | -8.41 Billion KRW | 39.43% |
| 2023 FY | -13.89 Billion KRW | -636.33% |
| 2023 Q3 | -19.47 Billion KRW | -2922.22% |
| 2023 Q1 | 1.52 Billion KRW | -41.13% |
| 2023 Q4 | -13.89 Billion KRW | 28.66% |
| 2023 Q2 | 689.95 Million KRW | -54.75% |
| 2022 Q2 | -72.66 Billion KRW | 4.39% |
| 2022 Q4 | 2.59 Billion KRW | 276.01% |
| 2022 FY | 2.59 Billion KRW | 108.02% |
| 2022 Q3 | 688.84 Million KRW | 100.95% |
| 2022 Q1 | -76 Billion KRW | -135.35% |
| 2021 FY | -32.29 Billion KRW | -427.28% |
| 2021 Q2 | 7.64 Billion KRW | -34.09% |
| 2021 Q3 | -77.13 Billion KRW | -1108.34% |
| 2021 Q4 | -32.29 Billion KRW | 58.13% |
| 2021 Q1 | 11.6 Billion KRW | 27.05% |
| 2020 Q4 | 9.13 Billion KRW | 212.17% |
| 2020 FY | 9.86 Billion KRW | 1160.17% |
| 2020 Q3 | -8.14 Billion KRW | -34.16% |
| 2020 Q2 | -6.07 Billion KRW | 44.69% |
| 2020 Q1 | -10.97 Billion KRW | -46.81% |
| 2019 FY | -930.75 Million KRW | 95.68% |
| 2019 Q4 | -7.47 Billion KRW | -158.85% |
| 2019 Q3 | 12.7 Billion KRW | -56.17% |
| 2019 Q2 | 28.98 Billion KRW | 193.52% |
| 2019 Q1 | -30.99 Billion KRW | -44.0% |
| 2018 Q4 | -21.52 Billion KRW | 45.72% |
| 2018 Q2 | -16.8 Billion KRW | 17.21% |
| 2018 Q3 | -39.65 Billion KRW | -135.94% |
| 2018 Q1 | -20.29 Billion KRW | 44.57% |
| 2018 FY | -21.52 Billion KRW | 41.23% |
| 2017 Q2 | -2.84 Billion KRW | -112.22% |
| 2017 Q1 | 23.26 Billion KRW | 201.68% |
| 2017 Q4 | -36.62 Billion KRW | -6.19% |
| 2017 Q3 | -34.48 Billion KRW | -1113.38% |
| 2017 FY | -36.62 Billion KRW | -574.96% |
| 2016 Q2 | 30.98 Billion KRW | 222.0% |
| 2016 Q4 | 7.71 Billion KRW | -70.46% |
| 2016 Q3 | 26.09 Billion KRW | -15.78% |
| 2016 Q1 | -25.39 Billion KRW | 44.08% |
| 2016 FY | 7.71 Billion KRW | 116.98% |
| 2015 Q1 | -6.23 Billion KRW | -159.38% |
| 2015 Q3 | -1.75 Billion KRW | 58.42% |
| 2015 Q4 | -45.42 Billion KRW | -2482.54% |
| 2015 Q2 | -4.22 Billion KRW | 32.16% |
| 2015 FY | -45.42 Billion KRW | -532.56% |
| 2014 FY | 10.5 Billion KRW | 0.0% |
| 2014 Q4 | 10.5 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 69.921% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 65.771% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 130.634% |
| Bioneer Corporation | -3.9 Billion KRW | -255.485% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 266.331% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 193.771% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 254.49% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 43.127% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 103.572% |
| Medy-Tox Inc. | 49.58 Billion KRW | 128.016% |
| Peptron, Inc. | 4.86 Billion KRW | 385.329% |
| Amicogen, Inc. | 125.26 Billion KRW | 111.09% |
| Genexine, Inc. | 61.39 Billion KRW | 122.626% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | -1.496% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 75.217% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 125.932% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 57.826% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 116.483% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 150.746% |
| Genomictree Inc. | -43.43 Billion KRW | 68.018% |
| MedPacto, Inc. | -64 Billion KRW | 78.295% |
| D&D Pharmatech | -7.5 Billion KRW | -85.029% |
| EASY BIO,Inc. | 53.21 Billion KRW | 126.107% |
| GI Innovation, Inc. | -4.82 Billion KRW | -188.057% |